ERBB2 and triple-negative breast carcinoma: The most common subtype was hormone receptor-positive, HER2-negative breast cancer (28 of 55, 50.9%), followed by triple-negative breast cancer (TNBC, 23 of 55, 41.8%), and hormone receptor-positive, HER2-positive breast cancer (2 of 55, 3.6%).